• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Emiglitate Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754826

MBS5754826 is an inhibitor targeting Emiglitate. Emiglitate is a selective and competitive alpha-glucoside hydrolase inhibitor. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Emiglitate, Inhibitor
Full Product Name
Emiglitate
Product Synonym Names
BAY o 1248
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
355.38
Solubility
<1mg/ml refers to the product slightly soluble or insoluble
Formula
C17H25NO7
SMILES
O=C(OCC)C1=CC=C(OCCN2[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C2)C=C1
CAS Number
80879-63-6
Target & IC50
Others
In Vitro
Emiglitate in the amount of 5mg/kg b.wt. does not induce significant changes either of glycogen concentrations or at the EM-level. Emiglitate causes a significant, dose-dependent increase of hepatic glycogen concentrations, in fasted rats. The increase in hepatic glycogen is due to lysosomal storage of glycogen only [2].

Product References and Citations for Emiglitate, inhibitor

Mosen H, et al. Nitric oxide inhibits, and carbon monoxide activates, islet acid alpha-glucoside hydrolase activitiesin parallel with glucose-stimulated insulin secretion. J Endocrinol. 2006 Sep;190(3):681-93.
Mosen H, et al. Nitric oxide inhibits, and carbon monoxide activates, islet acid alpha-glucoside hydrolase activitiesin parallel with glucose-stimulated insulin secretion. J Endocrinol. 2006 Sep;190(3):681-93.
Lembcke B, et al. Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II). Res Exp Med (Berl). 1991;191(6):389-404.
Lembcke B, et al. Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II). Res Exp Med (Berl). 1991;191(6):389-404.

Other Notes

Small volumes of Emiglitate, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000